Skip to main content
Top
Published in: Current Rheumatology Reports 5/2013

01-05-2013 | OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Osteoarthritis and Osteoporosis: What Is the Overlap?

Authors: Irene E. M. Bultink, Willem F. Lems

Published in: Current Rheumatology Reports | Issue 5/2013

Login to get access

Abstract

Osteoarthritis (OA) and osteoporosis (OP) are highly prevalent health problems, associated with considerable morbidity. In the past, attention was focused on a supposed inverse relationship between OA and OP, since both disorders usually affect the elderly, but were regarded to rarely coexist in a single person. However, recent studies have revealed several factors which contribute to the pathogenesis of both disorders. These insights might contribute to the development of shared new treatment options in the near future. Increased subchondral bone loss is a characteristic feature of OP and the early stage of OA, and this finding is the rationale for studies on the effect of anti-osteoporotic drugs in OA. In addition, inflammation and unfavourable body composition have been recognized as contributing factors for both disorders. Underweight is a risk factor for OP, while obesity stimulates the development of OA, by mechanical overloading of weight-bearing joints but also by supposed unfavourable effects of adipokines.
Literature
1.
go back to reference Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res. 2003;15:426–39.PubMed Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res. 2003;15:426–39.PubMed
2.
go back to reference Hart DJ, Mootoosamy I, Doyle DV, et al. The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study. Ann Rheum Dis. 1994;53:158–62.PubMedCrossRef Hart DJ, Mootoosamy I, Doyle DV, et al. The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study. Ann Rheum Dis. 1994;53:158–62.PubMedCrossRef
3.
go back to reference Healey JH, Vigorita VJ, Lane JM. The coexistence and characteristics of osteoarthritis and osteoporosis. J Bone Joint Surg Am. 1985;67:586–92.PubMed Healey JH, Vigorita VJ, Lane JM. The coexistence and characteristics of osteoarthritis and osteoporosis. J Bone Joint Surg Am. 1985;67:586–92.PubMed
4.
go back to reference Lafeber FPJG, Van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis. 2013;72:157–61.PubMedCrossRef Lafeber FPJG, Van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis. 2013;72:157–61.PubMedCrossRef
5.
go back to reference •• Bijlsma JWJ, Berenbaum E, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115–26. This is an outstanding state-of-the-art article on the epidemiology, etiology, clinical characteristics, diagnostic measures, and therapeutic options for osteoarthritis.PubMedCrossRef •• Bijlsma JWJ, Berenbaum E, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115–26. This is an outstanding state-of-the-art article on the epidemiology, etiology, clinical characteristics, diagnostic measures, and therapeutic options for osteoarthritis.PubMedCrossRef
6.
go back to reference Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139:330–6.PubMed Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003;139:330–6.PubMed
7.
go back to reference Berry PA, Maciewicz RA, Cicuttini FM, et al. Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss. J Rheumatol. 2010;37:1252–9.PubMedCrossRef Berry PA, Maciewicz RA, Cicuttini FM, et al. Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss. J Rheumatol. 2010;37:1252–9.PubMedCrossRef
8.
go back to reference Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230–7.PubMedCrossRef Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230–7.PubMedCrossRef
9.
go back to reference Zhang ZM, Li ZC, Jiang LS, et al. Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis. Osteoporos Int. 2010;21:1383–90.PubMedCrossRef Zhang ZM, Li ZC, Jiang LS, et al. Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis. Osteoporos Int. 2010;21:1383–90.PubMedCrossRef
10.
go back to reference Funck-Brentano T, Cohen-Solal M. Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev. 2011;22:91–7.PubMedCrossRef Funck-Brentano T, Cohen-Solal M. Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev. 2011;22:91–7.PubMedCrossRef
11.
go back to reference Bultink IEM, Vis M, Van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224–30.PubMedCrossRef Bultink IEM, Vis M, Van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224–30.PubMedCrossRef
12.
go back to reference Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRef Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRef
13.
go back to reference •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415–9. This is an excellent state-of-the-art article on bone biology.PubMedCrossRef •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415–9. This is an excellent state-of-the-art article on bone biology.PubMedCrossRef
14.
go back to reference • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13:242. Epub. This article is a large overview on osteoimmunology and osteoporosis.PubMedCrossRef • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13:242. Epub. This article is a large overview on osteoimmunology and osteoporosis.PubMedCrossRef
15.
go back to reference Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arhritis-induced osteoporosis. Rheumatol Int. 2012;32:3397–403.PubMedCrossRef Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arhritis-induced osteoporosis. Rheumatol Int. 2012;32:3397–403.PubMedCrossRef
16.
go back to reference Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med. 2006;166:2495–501.PubMedCrossRef Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med. 2006;166:2495–501.PubMedCrossRef
17.
go back to reference • Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69:761–5. This is an excellent systematic review on the association between obesity and hand osteoarthritis.PubMedCrossRef • Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69:761–5. This is an excellent systematic review on the association between obesity and hand osteoarthritis.PubMedCrossRef
19.
go back to reference Berenbaum F, Wymard F, Houard X. Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol. 2013;25:114–8.PubMedCrossRef Berenbaum F, Wymard F, Houard X. Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol. 2013;25:114–8.PubMedCrossRef
20.
go back to reference Filková M, Lišková M, Hulejová H, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis. 2009;68:295–6.PubMedCrossRef Filková M, Lišková M, Hulejová H, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis. 2009;68:295–6.PubMedCrossRef
21.
go back to reference Choe JY, Bae J, Jung HY, et al. Serum resistin level is associated with radiographic changes in hand osteoarthritis: cross-sectional study. Joint Bone Spine. 2012;79:160–5.PubMedCrossRef Choe JY, Bae J, Jung HY, et al. Serum resistin level is associated with radiographic changes in hand osteoarthritis: cross-sectional study. Joint Bone Spine. 2012;79:160–5.PubMedCrossRef
22.
go back to reference Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011;70:282–4. Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011;70:282–4.
23.
go back to reference Honsawek H, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res. 2010;41:593–8.PubMedCrossRef Honsawek H, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res. 2010;41:593–8.PubMedCrossRef
24.
go back to reference Koskinen A, Juslin S, Nieminen R, et al. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther. 2011;13:R184.PubMedCrossRef Koskinen A, Juslin S, Nieminen R, et al. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther. 2011;13:R184.PubMedCrossRef
25.
go back to reference Berry PA, Jones SW, Cicuttini FM, Wluka AE, Maciewicz RA. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum. 2011;63:700–7.PubMedCrossRef Berry PA, Jones SW, Cicuttini FM, Wluka AE, Maciewicz RA. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum. 2011;63:700–7.PubMedCrossRef
26.
go back to reference Iwamoto J, Takeda T, Sato Y, Matsumoto H. Serum leptin concentration positively correlates with body weight and total fat mass in postmenopausal Japanese women with osteoarthritis of the knee. Arthritis. 2011;2011:580632.PubMedCrossRef Iwamoto J, Takeda T, Sato Y, Matsumoto H. Serum leptin concentration positively correlates with body weight and total fat mass in postmenopausal Japanese women with osteoarthritis of the knee. Arthritis. 2011;2011:580632.PubMedCrossRef
27.
go back to reference Anandacoomarasamy A, Giuffre BM, Leibman S, et al. Delayed gadolinium-enhanced magnetic resonance imaging of cartilage: clinical associations in obese adults. J Rheumatol. 2009;36:1056–62.PubMedCrossRef Anandacoomarasamy A, Giuffre BM, Leibman S, et al. Delayed gadolinium-enhanced magnetic resonance imaging of cartilage: clinical associations in obese adults. J Rheumatol. 2009;36:1056–62.PubMedCrossRef
28.
go back to reference Van Spil WE, Welsing PMJ, Kloppenburg M, et al. Cross-sectional and predictive associations between plasma adipokines and radiographic signs of early-stage knee osteoarthritis: data from CHECK. Osteoarthr Cartil. 2012;20:1278–85.PubMedCrossRef Van Spil WE, Welsing PMJ, Kloppenburg M, et al. Cross-sectional and predictive associations between plasma adipokines and radiographic signs of early-stage knee osteoarthritis: data from CHECK. Osteoarthr Cartil. 2012;20:1278–85.PubMedCrossRef
29.
go back to reference De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330–8.PubMedCrossRef De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330–8.PubMedCrossRef
30.
go back to reference Prieto-Alhambra D, Premaor MO, Fina Avilés F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27:294–300.PubMedCrossRef Prieto-Alhambra D, Premaor MO, Fina Avilés F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27:294–300.PubMedCrossRef
31.
go back to reference Armstrong ME, Cairns BJ, Banks E, et al. Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone. 2012;50:1394–400.PubMedCrossRef Armstrong ME, Cairns BJ, Banks E, et al. Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone. 2012;50:1394–400.PubMedCrossRef
32.
go back to reference Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture risk in men and women: an epidemiologic perspective. J Bone Miner Res. 2012;27:1–10.PubMedCrossRef Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture risk in men and women: an epidemiologic perspective. J Bone Miner Res. 2012;27:1–10.PubMedCrossRef
33.
go back to reference Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 2003;70:257–62.PubMedCrossRef Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 2003;70:257–62.PubMedCrossRef
34.
go back to reference Wilson MG, Michet Jr CJ, Ilstrup DM, et al. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc. 1990;65:1214–21.PubMedCrossRef Wilson MG, Michet Jr CJ, Ilstrup DM, et al. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc. 1990;65:1214–21.PubMedCrossRef
35.
go back to reference Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment – a systematic approach. Osteoarthr Cartil. 2008;16:533–41.PubMedCrossRef Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment – a systematic approach. Osteoarthr Cartil. 2008;16:533–41.PubMedCrossRef
36.
go back to reference Sniekers YH, Weinans H, van Osch GJ, et al. Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis. Arthritis Res Ther. 2010;12:R182.PubMedCrossRef Sniekers YH, Weinans H, van Osch GJ, et al. Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis. Arthritis Res Ther. 2010;12:R182.PubMedCrossRef
37.
go back to reference Richette P, Dumontier MF, Tahiri K, et al. Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment. Ann Rheum Dis. 2007;66:345–50.PubMedCrossRef Richette P, Dumontier MF, Tahiri K, et al. Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment. Ann Rheum Dis. 2007;66:345–50.PubMedCrossRef
38.
go back to reference Bay-Jensen AC, Tabassi NC, Sondergaard LV, et al. The response to estrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther. 2009;11:R9.PubMedCrossRef Bay-Jensen AC, Tabassi NC, Sondergaard LV, et al. The response to estrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther. 2009;11:R9.PubMedCrossRef
39.
go back to reference Mouritzen U, Christgau S, Lehmann HJ, et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003;62:332–6.PubMedCrossRef Mouritzen U, Christgau S, Lehmann HJ, et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003;62:332–6.PubMedCrossRef
40.
go back to reference Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause. 2004;11:508–18.PubMedCrossRef Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause. 2004;11:508–18.PubMedCrossRef
41.
go back to reference Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;11:3516–25.CrossRef Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;11:3516–25.CrossRef
42.
go back to reference Karsdal MA, Sondergaard BC, Arnold M, et al. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci. 2007;1117:181–95.PubMedCrossRef Karsdal MA, Sondergaard BC, Arnold M, et al. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci. 2007;1117:181–95.PubMedCrossRef
43.
go back to reference Sondergaard BC, Madsen SH, Segovia-Silvestre T, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2010;11:62.PubMedCrossRef Sondergaard BC, Madsen SH, Segovia-Silvestre T, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2010;11:62.PubMedCrossRef
44.
go back to reference Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205–11.PubMedCrossRef Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205–11.PubMedCrossRef
45.
go back to reference Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritis patients: a 14-day randomized study. Osteoarthr Cartil. 2010;18:150–9.PubMedCrossRef Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritis patients: a 14-day randomized study. Osteoarthr Cartil. 2010;18:150–9.PubMedCrossRef
46.
go back to reference Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425–30.PubMedCrossRef Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005;37:425–30.PubMedCrossRef
47.
go back to reference Saag KG. Bisphosphonates for osteoarthritis prevention: “Holy Grail” or not? Ann Rheum Dis. 2008;67:1358–9.PubMedCrossRef Saag KG. Bisphosphonates for osteoarthritis prevention: “Holy Grail” or not? Ann Rheum Dis. 2008;67:1358–9.PubMedCrossRef
48.
go back to reference Podworny NV, Kandel RA, Renlund RC, et al. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol. 1999;26:1972–82.PubMed Podworny NV, Kandel RA, Renlund RC, et al. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol. 1999;26:1972–82.PubMed
49.
go back to reference Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50:1193–206.PubMedCrossRef Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50:1193–206.PubMedCrossRef
50.
go back to reference Kadri A, Funck-Brentano T, Lin H, et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodeling. Ann Rheum Dis. 2010;69:1533–8.PubMedCrossRef Kadri A, Funck-Brentano T, Lin H, et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodeling. Ann Rheum Dis. 2010;69:1533–8.PubMedCrossRef
51.
go back to reference Moreau M, Rialland P, Pelletier JP, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011;13:R98.PubMedCrossRef Moreau M, Rialland P, Pelletier JP, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011;13:R98.PubMedCrossRef
52.
go back to reference Neogi T, Nevitt MC, Ensrud KE, et al. The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis. 2008;67:1427–30.PubMedCrossRef Neogi T, Nevitt MC, Ensrud KE, et al. The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis. 2008;67:1427–30.PubMedCrossRef
53.
go back to reference Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005;7:R625–33.PubMedCrossRef Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005;7:R625–33.PubMedCrossRef
54.
go back to reference Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symtpoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee. Arthritis Rheum. 2006;54:3493–507.CrossRef Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symtpoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee. Arthritis Rheum. 2006;54:3493–507.CrossRef
55.
go back to reference Buckland-Wright JC, Messent EA, Bingham CO, et al. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritis knee patients. Rheumatology. 2007;46:257–64.PubMedCrossRef Buckland-Wright JC, Messent EA, Bingham CO, et al. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritis knee patients. Rheumatology. 2007;46:257–64.PubMedCrossRef
56.
go back to reference Roux C, Richette P. Impact of treatments for osteoporosis on osteoarthritis progression. Osteoporos Int. 2012;23:S881–3.PubMedCrossRef Roux C, Richette P. Impact of treatments for osteoporosis on osteoarthritis progression. Osteoporos Int. 2012;23:S881–3.PubMedCrossRef
57.
go back to reference Laslett LL, Doré DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71:1322–8.PubMedCrossRef Laslett LL, Doré DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71:1322–8.PubMedCrossRef
58.
go back to reference Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone. 2007;40:S5–8.CrossRef Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone. 2007;40:S5–8.CrossRef
59.
go back to reference Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone. 2007;40:218–22.PubMedCrossRef Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone. 2007;40:218–22.PubMedCrossRef
60.
go back to reference Alexandersen P, Karsdal MA, Byrjalsen I, et al. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric. 2011;14:236–43.PubMedCrossRef Alexandersen P, Karsdal MA, Byrjalsen I, et al. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric. 2011;14:236–43.PubMedCrossRef
61.
go back to reference Van Spil WE, Drossaers-Bakker KW, Lafeber FPJG. Associations of CTX-II with biochemical markers of bone turnover rise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013;72:29–36.PubMedCrossRef Van Spil WE, Drossaers-Bakker KW, Lafeber FPJG. Associations of CTX-II with biochemical markers of bone turnover rise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013;72:29–36.PubMedCrossRef
62.
go back to reference Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis. 2008;67:335–9.PubMedCrossRef Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis. 2008;67:335–9.PubMedCrossRef
63.
go back to reference • Reginster J-Y, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179–86. In this article, the results of the first prospective, placebo-controlled, clinical study on the effect of strontium ranelate in the treatment of osteoarthritis (of the knee) are presented.PubMedCrossRef • Reginster J-Y, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179–86. In this article, the results of the first prospective, placebo-controlled, clinical study on the effect of strontium ranelate in the treatment of osteoarthritis (of the knee) are presented.PubMedCrossRef
64.
go back to reference Tat SK, Pelletier J-P, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone. 2011;49:559–67.PubMedCrossRef Tat SK, Pelletier J-P, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone. 2011;49:559–67.PubMedCrossRef
65.
go back to reference Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16:299–308.PubMedCrossRef Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16:299–308.PubMedCrossRef
66.
go back to reference Simpson ER, Hilton MJ, Tian Y, et al. Teriparatide, a chondro-regenerative therapy for injury-induced osteoarthritis. Sci Transl Med. 2011;3:101ra93.CrossRef Simpson ER, Hilton MJ, Tian Y, et al. Teriparatide, a chondro-regenerative therapy for injury-induced osteoarthritis. Sci Transl Med. 2011;3:101ra93.CrossRef
67.
go back to reference Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 1998;41:2152–64.PubMedCrossRef Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 1998;41:2152–64.PubMedCrossRef
68.
go back to reference Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone mineral density. J Bone Miner Res. 2010;25:937–47.PubMed Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone mineral density. J Bone Miner Res. 2010;25:937–47.PubMed
69.
go back to reference Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012;50:1250–9.PubMedCrossRef Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012;50:1250–9.PubMedCrossRef
Metadata
Title
Osteoarthritis and Osteoporosis: What Is the Overlap?
Authors
Irene E. M. Bultink
Willem F. Lems
Publication date
01-05-2013
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 5/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0328-0

Other articles of this Issue 5/2013

Current Rheumatology Reports 5/2013 Go to the issue

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Inhibition of Nitric Oxide and Antiphospholipid Antibody-Mediated Thrombosis

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTON EDITOR)

Update on Treatment of Inclusion Body Myositis

INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Infectious Complications in Juvenile Idiopathic Arthritis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.